Search
Search
Lloyd Clark, MD
Show Description +
Since the completion of two parallel phase 3 randomized, double-masked, multicenter clinical trials, VIEW 1 and VIEW 2, long-term outcomes of aflibercept (Eylea, Regeneron) have been assessed in further clinical trials. In this installment of the AMD Resource Center, W. Lloyd Clark, MD, summarizes some of the results of an extension study that included patients from the VIEW 1 trial, which accumulated data out to 4 years of follow-up, and the 1-year interim results of a further 2-year treat-and-extend follow-up study called RANGE
Posted: 11/29/2016
Lloyd Clark, MD
Since the completion of two parallel phase 3 randomized, double-masked, multicenter clinical trials, VIEW 1 and VIEW 2, long-term outcomes of aflibercept (Eylea, Regeneron) have been assessed in further clinical trials. In this installment of the AMD Resource Center, W. Lloyd Clark, MD, summarizes some of the results of an extension study that included patients from the VIEW 1 trial, which accumulated data out to 4 years of follow-up, and the 1-year interim results of a further 2-year treat-and-extend follow-up study called RANGE
Posted: 11/29/2016
![[2019] Amniotic Membrane Placement for Repair of Recurrent Macular Hole](https://d33x7gwyb2b5z6.cloudfront.net/eyetube/thumbs/gldaw.jpg?auto=compress,format&w=180)
Please log in to leave a comment.